LECTURE 32 Flashcards
What is cancer cachexia?
Multifactorial syndrome characterised by an ongoing loss of skeletal muscle mass with out without loss of fat mass that leads to progressive functional impairment
When is clinical diagnosis of cancer cachexia made?
- Weight loss >5% over the past 6 months in absence of starvation
- BMI 2%
- Appendicular skeletal muscle index consistent with sarcopenia (M: >7.26kg/m2, F: 2%
What percentage of cancer patients does cachexia affect?
> 80%
What percentage of patients with pancreatic or gut cancers have cachexia?
80%
What percentage of patients with prostate, colon or lung cancers have cachexia?
50%
What groups of people is cachexia more common in?
Children and elderly
How many new cases of cancer and how many deaths per year?
115,000, 43,000 (most from cachexia)
What are the consequences of cancer cachexia that lead to reduced quality of life?
- Decreased muscle function
- Impaired mobility (40% drop in physical activity)
- Enhanced fatigue
- Reduced independence
- Premature retirement
- Increase incidence of metabolic disease
- Increased risk of complications during surgery
What are the consequences of cancer cachexia that lead to death?
Impaired response to chemo and radiotherapy, cardiac failure, respiratory failure
What does C-26 injected into rats do?
Loss of muscle mass, spinal kyphosis and resp failure (severe has more similarities to human condition than mild)
What happens to mice with severe or mild cachexia after chemotherapy?
Severe: 42% reduction in tumour size
Mild: 82% reduction in tumour size
What happens to the diaphragm in cachectic mice?
Reduced force producing capacity, tidal volume and ventilation
What factors were altered in cadavers with cancer cachexia?
Heart mass, structural remodelling, cardiac fibrosis, systolic dysfunction (reduced ejection fraction)
What percentage of deaths is cancer cachexia responsible for?
20-30% of all cancer related deaths
What is muscle mass a predictor of in cancer patients?
Toxicity associated with chemotherapy, chance of remaining failure free after chemotherapy and survival